June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Anti-Inflammatory and Anti-Fibrotic Activities of Human Corneal Stromal Stem Cells and Their Extracellular Vesicles Measured by in vitro Assays
Author Affiliations & Notes
  • Bryan Le
    Ophthalmology, University of California Los Angeles, Los Angeles, California, United States
    Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
  • Rob Knight
    Ophthalmology, University of California Los Angeles, Los Angeles, California, United States
  • Sarah Robertson
    Ophthalmology, University of California Los Angeles, Los Angeles, California, United States
  • Sophie Xiaohui Deng
    Ophthalmology, University of California Los Angeles, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Bryan Le None; Rob Knight None; Sarah Robertson None; Sophie Deng None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 116 – A0214. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Bryan Le, Rob Knight, Sarah Robertson, Sophie Xiaohui Deng; Anti-Inflammatory and Anti-Fibrotic Activities of Human Corneal Stromal Stem Cells and Their Extracellular Vesicles Measured by in vitro Assays. Invest. Ophthalmol. Vis. Sci. 2022;63(7):116 – A0214.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Human Corneal Stromal Stem Cells (CSSC) have been shown to promote regeneration of transparent stromal tissue and suppress inflammation in wounded mouse corneas. Small extracellular vesicles (sEV) secreted by these CSSC have been implicated to play a crucial role in this process. It is important to identify those CSSC that display high regenerative capacity. This study investigated the capacity of CSSC and their sEVs to suppress inflammation and fibrosis using in vitro assays.

Methods : Conditioned media of primary human CSSC were collected for sEV isolation and assay analysis. Anti-inflammatory response was evaluated using a RAW 264.7 cell assay, in which osteoclast differentiation was induced by receptor activator of nuclear factor kappa-Β ligand (RANKL) and Concanavalin A. Cell morphology and mRNA level of matrix metalloproteinase 9 (MMP-9), Tartrate resistant acid phosphatase (ACP5), and Cathepsin K (CTSK) was quantified by qRT-PCR. Anti-fibrotic activity was assessed by a differentiation protocol in which primary human corneal fibroblasts differentiated into myofibroblasts after TGF-β1 treatment and were assayed for pro-collagen I alpha-1 (pro-COLIa1) level via ELISA and the protein expression of myofibroblast markers, α-smooth muscle actin (αSMA) and fibronectin extra domain-A (EDA-FN) by immunohistochemistry.

Results : Conditioned media and sEVs from primary CSSCs were capable of significantly reducing gene expression of MMP-9 (5.37 folds and 2.07 folds, respectively, p<0.05), CTSK (2.1 and 3 folds, p<0.05), and ACP5 (2.2 and 2.1 folds, p<0.05) compared to the positive control in the RAW 264.7 cell assay. CSSC conditioned media potency correlates with their sEVs’ potency to prevent monocyte-to-osteoclast differentiation. In anti-fibrotic assays, sEVs from CSSC reduced pro-COLIa1 level by 40.9% relative to the positive control and lowered αSMA-positive cells by 32% (p<0.001). Among these different CSSC derived from multiple donors, one distinct donor CSSC produced sEVs that repeatedly demonstrate a higher anti-inflammatory and anti-fibrotic capacity than other CSSC (p<0.001).

Conclusions : The anti-fibrotic activity of sEV could be quantified using in vitro assays. There is donor variation among CSSCs and their sEVs in respect to their anti-inflammatory and anti-fibrotic capacity. The factors didact the activities of sEV remain to be elucidated.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×